CA Patent

CA3166250A1 — Drug products for intranasal administration and uses thereof

Assigned to Summit Biosciences Inc · Expires 2021-08-12 · 5y expired

What this patent protects

Provided herein are drug products adapted for nasal delivery comprising a device and a pharmaceutical composition comprising an opioid receptor antagonist or unit doses thereof, pharmaceutical compositions comprising an opioid receptor antagonist, and methods of use and preparati…

USPTO Abstract

Provided herein are drug products adapted for nasal delivery comprising a device and a pharmaceutical composition comprising an opioid receptor antagonist or unit doses thereof, pharmaceutical compositions comprising an opioid receptor antagonist, and methods of use and preparation thereof.

Drugs covered by this patent

Patent Metadata

Patent number
CA3166250A1
Jurisdiction
CA
Classification
—
Expires
2021-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Summit Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.